Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDNA Stock Forecast 2026-2027
$22.25
Current Price
$1.13B
Market Cap
Buy 3
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to CDNA Price Targets
+25.8%
To High Target of $28.00
+16.9%
To Median Target of $26.00
-5.6%
To Low Target of $21.00
CDNA Price Momentum
+0.8%
1 Week Change
+2.0%
1 Month Change
+12.8%
1 Year Change
+18.1%
Year-to-Date Change
-7.4%
From 52W High of $24.02
+103.0%
From 52W Low of $10.96
📊 TOP ANALYST CALLS
Did CDNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CareDx is one of their latest high-conviction picks.
Latest CDNA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CDNA has a neutral consensus with a median price target of $26.00 (ranging from $21.00 to $28.00). The overall analyst rating is Buy (7.7/10). Currently trading at $22.25, the median forecast implies a 16.9% upside. This outlook is supported by 3 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mark Massaro at BTIG, projecting a 25.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDNA Analyst Ratings
3
Buy
4
Hold
0
Sell
CDNA Price Target Range
Low
$21.00
Average
$26.00
High
$28.00
Current: $22.25
Latest CDNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 29, 2026 | BTIG | Mark Massaro | Buy | Maintains | $28.00 |
| Feb 26, 2026 | BTIG | Buy | Maintains | $N/A | |
| Feb 25, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Dec 15, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 6, 2025 | BTIG | Buy | Maintains | $N/A | |
| Sep 23, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 12, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Aug 26, 2025 | William Blair | Market Perform | Initiates | $N/A | |
| Aug 8, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jul 18, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| May 5, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| May 5, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Apr 17, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| Mar 3, 2025 | HC Wainwright & Co. | Neutral | Maintains | $N/A | |
| Feb 27, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Jan 15, 2025 | Wells Fargo | Equal-Weight | Upgrade | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Nov 5, 2024 | BTIG | Buy | Maintains | $N/A | |
| Oct 22, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Oct 16, 2024 | Goldman Sachs | Buy | Maintains | $N/A |
CareDx Inc. (CDNA) Competitors
The following stocks are similar to CareDx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CareDx Inc. (CDNA) Financial Data
CareDx Inc. has a market capitalization of $1.13B with a P/E ratio of 14.0x. The company generates $412.82M in trailing twelve-month revenue with a -2.0% profit margin.
Revenue growth is +39.0% quarter-over-quarter, while maintaining an operating margin of +1.5% and return on equity of -2.4%.
Valuation Metrics
Market Cap
$1.13B
Enterprise Value
$986.75M
P/E Ratio
14.0x
PEG Ratio
-0.1x
Price/Sales
2.8x
Growth & Margins
Revenue Growth (YoY)
+39.0%
Gross Margin
+71.4%
Operating Margin
+1.5%
Net Margin
-2.0%
EPS Growth
+39.0%
Financial Health
Cash/Price Ratio
+16.3%
Current Ratio
3.4x
Debt/Equity
7.8x
ROE
-2.4%
ROA
-1.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CareDx Inc. (CDNA) Business Model
About CareDx Inc.
What They Do
Develops diagnostic solutions for transplant patients.
Business Model
CareDx Inc. generates revenue through its precision medicine offerings, which include genomics-based testing services for transplant patients. The company sells its diagnostic tests, high-quality lab products, and digital solutions, catering to transplant centers, clinicians, and biopharma partners, thereby enhancing patient care and improving transplant outcomes.
Additional Information
Founded in 1998 and based in Brisbane, California, CareDx Inc. is at the forefront of advancing transplant medicine with its innovative technologies and comprehensive patient solutions. Its products support donor-recipient matching and patient monitoring, positioning the company as a critical player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
644
CEO
Mr. John Walter Hanna Jr.
Country
United States
IPO Year
2014
Website
caredx.comCareDx Inc. (CDNA) Latest News & Analysis
Latest News
Quick Summary
CareDx, Inc. (Nasdaq: CDNA) will present at the Jefferies 2026 Global Healthcare Conference on June 3, 2026, in New York, focusing on transplant healthcare solutions.
Why It Matters
CareDx's participation in major investor conferences signals potential growth and innovation in the transplant sector, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
CareDx Announces Dismissal of 2021 Qui Tam Suit
28 days ago
Quick Summary
CareDx, Inc. announced the dismissal of a qui tam action against the company by the U.S. District Court for the Eastern District of New York on April 23, 2026.
Why It Matters
The dismissal of the qui tam action against CareDx reduces legal risks and potential financial liabilities, positively impacting investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. (CDNA) held its Q1 2026 earnings call, providing updates on financial performance and strategic initiatives. Key financial metrics and future outlook were discussed.
Why It Matters
CareDx's Q1 2026 earnings results indicate financial health and growth potential, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. awarded restricted stock units (RSUs) to 23 new employees as an inducement for employment, effective April 30, 2026.
Why It Matters
CareDx's inducement grants signal growth and hiring, suggesting confidence in future performance, which can positively impact stock value and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CareDx, Inc. reported Q1 2026 revenue of $118 million, a 39% increase year-over-year, with testing services revenue at $91 million.
Why It Matters
CareDx's 39% revenue growth signals strong demand for its transplant solutions, enhancing its market position and potential for future profitability, which may attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
1 month ago
Quick Summary
CareDx, Inc. (Nasdaq: CDNA) has agreed to acquire Naveris, a precision oncology diagnostics company, enhancing its portfolio in transplant and oncology solutions.
Why It Matters
CareDx's acquisition of Naveris enhances its portfolio in precision medicine, potentially boosting revenue and market position in the oncology space, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CDNA Stock
What is CareDx Inc.'s (CDNA) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, CareDx Inc. (CDNA) has a median price target of $26.00. The highest price target is $28.00 and the lowest is $21.00.
Is CDNA stock a good investment in 2026?
According to current analyst ratings, CDNA has 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $22.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDNA stock?
Wall Street analysts predict CDNA stock could reach $26.00 in the next 12 months. This represents a 16.9% increase from the current price of $22.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CareDx Inc.'s business model?
CareDx Inc. generates revenue through its precision medicine offerings, which include genomics-based testing services for transplant patients. The company sells its diagnostic tests, high-quality lab products, and digital solutions, catering to transplant centers, clinicians, and biopharma partners, thereby enhancing patient care and improving transplant outcomes.
What is the highest forecasted price for CDNA CareDx Inc.?
The highest price target for CDNA is $28.00 from Mark Massaro at BTIG, which represents a 25.8% increase from the current price of $22.25.
What is the lowest forecasted price for CDNA CareDx Inc.?
The lowest price target for CDNA is $21.00 from at , which represents a -5.6% decrease from the current price of $22.25.
What is the overall CDNA consensus from analysts for CareDx Inc.?
The overall analyst consensus for CDNA is neutral. Out of 2 Wall Street analysts, 3 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $26.00.
How accurate are CDNA stock price projections?
Stock price projections, including those for CareDx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 9:18 PM UTC